title: [Meningococcus B vaccine: a new tool against invasive bacteric diseases].
abstract: After the introduction of the conjugate vaccine against meningococcus C, serogroup B became the main agent of meningococcal disease in Europe. A new approach called "reverse vaccinology" was applied to identify new antigenic proteins able to induce the production of bactericidal antibodies. The final formulation of the vaccine against serogroup B contains three antigens and the outer membrane vesicles derived from MenZB vaccine used in New Zealand. The vaccine has proved to be highly immunogenic against a wide range of meningococcus B strains in all age groups.
authors.affiliation: Scuola di Specializzazione in Igiene e Medicina Preventiva, Università di Roma Tor Vergata.
authors.forename: Cristiana
authors.initials: C
authors.lastname: Carlino
authors.forename: Laura
authors.initials: L
authors.lastname: Zaratti
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Franco
mesh_terms: D006801:Humans; D008589:Meningococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*
chemical_list: D022401:Meningococcal Vaccines